Table 1 Showed clinical characteristics of studied patients with COVID-19 under tocilizumab or pulse Dexamethasone therapy.

From: Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab

 

COVID-19 patients under tocilizumab Therapy

COVID-19 patients under pulse Dexamethasone Therapy

P value

Number

46

63

 

The median age (IQR [interquartile range]) / years

60.5 (49.5, 66.5)

64 (55, 72)

0.056

Sex (male / female)

(26/ 20)

(36/ 27)

0.948

PaO2/FiO2 before treatment median (IQR)

84 (75.75, 96.25)

82 (70, 90)

0.2

PaO2/FiO2 2 days after treatment median (IQR)

82 .2 (78, 124)

92 (71, 129)

0.344

Neutrophiles/ Lymphocytes ratio median (IQR)

3.72 (3.62, 4.11)

3.69 (3.1, 3.69)

0.057

D-dimer ng/mL median (IQR)

1420 (420, 3720)

1400 (750, 3200)

0.897

Ferritin ng/mL median (IQR)

1153.5 (661, 1562.5)

934 (623, 1357)

0.124

NIV/ MV

32/14

38/25

0.32

CT Chest

   

GGO/Consolidation

16/30

20/43

0.448

Vasopressor before treatment

28

27

0.081

Comorbidities number (%)

Diabetes mellites

16 (34.8%)

15 (23.8%)

0.149

Hypertension

26 (56.5%)

26 (41.3%)

0.84

Heart diseases

0

14 (22.2%)

 < 0.0001

Kidney disease

4 (8.7%)

5 (7.9%)

 0.576

Cancer

0

1 (1.6%)

0.578

Hyperthyroidism

0

1 (1.6%)

0.578

hepatitis C virus

2 (4.3%)

2 (3.2%)

0.565

COPD

0

2 (3.2%)

0.332

Asthma

0

3 (4.8%)

0.189

Deaths number (%)

32 (69.6%)

33 (52.4%)

0.05

Nasocomial pneumonia

14 (30.4%)

16 (25.4%)

 0.356

Hyper glycemia

6 (13%)

9 (14.3%)

 0.542

Renal impairment

3 (6.5%)

2 (3.2%)

 0.353

Increased liver enzymes

6 (13%)

5 (7.9%)

 0.288

Pulmonary embolism

3 (6.5%)

1 (1.6%)

 0.201

  1. Abbreviations MV: mechanical ventilation; NIV: Non-invasive ventilation; PaO2/FiO2: ratio of partial pressure of arterial oxygen over fraction of inspired oxygen; P ˂ 0.05 considered statistically significant. GGO ground glass opacities.
Back to article page